Published in Gynecol Oncol on October 27, 2006
Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health (2010) 0.89
Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol. BMC Cancer (2007) 0.85
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol (2008) 0.80
Fatigue, Mood, and Sleep, During Intraperitoneal Chemotherapy: A Pilot Case Control Study. Int J Psychol Res (Medellin) (2013) 0.75
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2006) 4.33
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (1978) 2.42
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol (2006) 1.61
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (1979) 1.55
Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res (1989) 1.55
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol (1992) 1.54
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol (1996) 1.28
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (1995) 1.23
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res (1980) 1.20
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol (1995) 1.18
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol (1987) 1.17
Camptothecins: a review of their development and schedules of administration. Eur J Cancer (1998) 1.12
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol (1999) 1.06
Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep (1983) 1.02
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol (2002) 0.99
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer (2003) 0.98
A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res (1992) 0.96
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol (1991) 0.95
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol (1984) 0.93
Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol (1990) 0.90
Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol (1998) 0.89
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol Oncol (1997) 0.87
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res (2005) 0.87
The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res (1980) 0.86
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol (1992) 0.82
Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group. Gynecol Oncol (1996) 0.81
Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens. Gynecol Oncol (1993) 0.79
Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin). Gynecol Oncol (1997) 0.77
A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry (1978) 25.54
The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell (1988) 10.47
Cornell Scale for Depression in Dementia. Biol Psychiatry (1988) 6.61
'Vascular depression' hypothesis. Arch Gen Psychiatry (1997) 6.59
Genome-wide distribution of ORC and MCM proteins in S. cerevisiae: high-resolution mapping of replication origins. Science (2001) 6.06
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck. Nature (1989) 5.20
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res (1985) 5.09
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA (1998) 5.09
Isolation and functional characterization of human intestinal mucosal lymphoid cells. J Clin Invest (1977) 5.09
In vivo high-resolution video-rate spectral-domain optical coherence tomography of the human retina and optic nerve. Opt Express (2004) 4.96
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 4.40
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (1977) 3.11
Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse. Mol Cell Biol (1998) 3.09
Age- and sex-related risk factors for adolescent suicide. J Am Acad Child Adolesc Psychiatry (1999) 2.99
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol (1974) 2.89
A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum (1996) 2.87
CheA protein, a central regulator of bacterial chemotaxis, belongs to a family of proteins that control gene expression in response to changing environmental conditions. Proc Natl Acad Sci U S A (1988) 2.85
Controlled production of proliferating somatic cell hybrids. J Cell Biol (1970) 2.78
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol (1973) 2.61
The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol (2000) 2.37
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood (1998) 2.36
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med (1974) 2.25
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
An outcomes assessment of intra-articular calcaneal fractures, using patient and physician's assessment profiles. Injury (2003) 2.16
Tumor chemosensitivity and chemoresistance assays. Cancer (1996) 2.14
Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. N Engl J Med (1980) 2.07
Clinically defined vascular depression. Am J Psychiatry (1997) 2.06
Identification of a possible nucleotide binding site in CheW, a protein required for sensory transduction in bacterial chemotaxis. J Biol Chem (1987) 2.05
Biological degradation of resin acids in wood chips by wood-inhabiting fungi. Appl Environ Microbiol (1995) 2.04
Staging laparotomy in early ovarian cancer. JAMA (1983) 2.02
The anthracycline antineoplastic drugs. N Engl J Med (1981) 2.02
TB testing. Vet Rec (1996) 2.01
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Invasive aspergillosis. Absence of detectable antibody response. Am Rev Respir Dis (1971) 1.96
The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry (1993) 1.92
Energy-dependent calcium sequestration activity in rat liver microsomes. J Biol Chem (1975) 1.91
Alterations of the lymphocyte-specific protein tyrosine kinase (p56lck) during T-cell activation. Mol Cell Biol (1988) 1.90
GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors (2001) 1.88
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Sequence requirements of Escherichia coli attTn7, a specific site of transposon Tn7 insertion. J Bacteriol (1988) 1.85
Regulation of macrophage activation. Cell Mol Life Sci (2003) 1.83
Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem (2000) 1.82
Characteristics of isolated intestinal mucosal lymphoid cells in inflammatory bowel disease. Gastroenterology (1979) 1.81
A localized GTPase exchange factor, Bud5, determines the orientation of division axes in yeast. Curr Biol (2001) 1.79
Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry (2000) 1.78
Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches. Semin Hematol (1972) 1.78
Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature (1973) 1.78
Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol (1999) 1.77
Umbilical cord plasma 25-hydroxyvitamin D concentration and immune function at birth: the Urban Environment and Childhood Asthma study. Clin Exp Allergy (2011) 1.76
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res (2001) 1.76
Mapping of a human genetic regulator element by somatic cell genetic analysis. Proc Natl Acad Sci U S A (1970) 1.76
Chemotherapy of ovarian cancer. Semin Oncol (1984) 1.75
Localization of the immune response in sarcoidosis. Am Rev Respir Dis (1979) 1.74
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Bacillus cereus panophthalmitis: source of the organism. Rev Infect Dis (1982) 1.74
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A (1987) 1.71
Complete closure of large gastric defects after endoscopic full-thickness resection, using endoloop and metallic clip interrupted suture. Endoscopy (2013) 1.69
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann Oncol (2009) 1.67
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer (1975) 1.66
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol (2001) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Ecdysteroid regulation and DNA binding properties of Drosophila nuclear hormone receptor superfamily members. Dev Biol (1995) 1.60
Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol (2000) 1.58
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med (1983) 1.58
Vagus nerve stimulation activates central nervous system structures in epileptic patients during PET H2(15)O blood flow imaging. Neurosurgery (1996) 1.57
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol (1996) 1.57
Alcoholic hyalin antigen (AHAg) and antibody (AHAb) in alcoholic hepatitis. Gastroenterology (1977) 1.57
Cloning of the Streptococcus mutans gene encoding glucan binding protein B and analysis of genetic diversity and protein production in clinical isolates. Infect Immun (2001) 1.56
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res (1988) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Alterations in tyrosine protein phosphorylation induced by antibody-mediated cross-linking of the CD4 receptor of T lymphocytes. Mol Cell Biol (1989) 1.55
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (1979) 1.55
Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. J Clin Oncol (1997) 1.55
Disability in geriatric depression. Am J Psychiatry (1996) 1.55
7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J Clin Invest (2001) 1.55
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol (1992) 1.54
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53